Delfi 正在开发一种新的液体活检测试，用于基于改变的全基因组片段化谱进行早期检测，也称为“片段组”，代表癌细胞中 DNA 的异常包装。通过应用先进的机器学习算法，可以以非常低的测序成本检测到这些片段模式。 Delfi（“早期拦截片段的 DNA 评估”）正在使用该技术开发高度敏感和特异性的癌症检测分析，旨在广泛且具有成本效益的分发和采用。
消息来源 Delfi 诊断作者: StephenW 时间: 2022-10-28 14:30
Researchers to Present Proof-of-Concept Liver Cancer Detection Data Using the DELFI Platform at AASLD The Liver Meeting® 2022
News provided by
Delfi Diagnostics
Oct 27, 2022, 11:00 ET
Share this article
BALTIMORE and PALO ALTO, Calif., Oct. 27, 2022 /PRNewswire/ -- Researchers using the DELFI platform, a technology for a new class of high performance, accessible liquid biopsy tests being commercialized by Delfi Diagnostics, Inc., will present new data demonstrating its ability to accurately detect liver cancer in high risk and average risk individuals at The Liver Meeting 2022, the annual meeting of the American Association for the Study of Liver Disease.
Researchers to Present Proof-of-Concept Liver Cancer Detection Data Using the DELFI Platform at AASLD The Liver Meeting® 2022
Researchers to Present Proof-of-Concept Liver Cancer Detection Data Using the DELFI Platform at AASLD The Liver Meeting® 2022
Liver cancer is the sixth leading cancer killer in the United States and the third-leading cause of cancer-related deaths world wide. Globally, the high-risk population of over 350 million individuals is growing due to increases in fatty liver disease, cirrhosis, and chronic viral hepatitis infections. Meanwhile, screening rates remain below 20 percent in the U.S. and worldwide, despite longstanding recommendations for screening high-risk patients.
Researchers will present preliminary findings showing its platform can accurately and cost-effectively distinguish patients with hepatocellular carcinoma (HCC) from individuals without cancer, even when they suffer from other comorbidities.
"Liver cancer is the fastest growing cancer killer and is projected to become the third leading cause of cancer deaths in the U.S. by 2035. This is an exciting demonstration of the potential for Delfi's platform to address a growing public health problem," said Peter B. Bach, Delfi's Chief Medical Officer.
Oral Presentation Details:
Cell-free DNA fragmentomes for detection of liver cancer
Authors: Zachariah H. Foda, et. al
Session: Novel Approaches for Risk Stratification and Surveillance for HCC
Date: Monday, November 7, 2022
Time: 9:00 - 10:30 AM EST
About Delfi Diagnostics
Delfi is developing a new class of liquid biopsy tests for early detection based on altered genome-wide fragmentation profiles, also known as "fragmentomes," representing aberrant packaging of DNA in cancer cells. By applying advanced machine learning algorithms, these fragment patterns are detectable at a very low sequencing cost. Delfi ("DNA Evaluation of Fragments for early Interception") is using this technology to develop highly sensitive and specific cancer detection assays intended for wide and cost-effective distribution and adoption.